Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes

Details for Australian Patent Application No. 2006297128 (hide)

Owner Novartis AG

Inventors Kirman, Louise; Bebernitz, Gregory Raymond

Agent Davies Collison Cave

Pub. Number AU-B-2006297128

PCT Pub. Number WO2007/041366

Priority 60/722,630 30.09.05 US

Filing date 28 September 2006

Wipo publication date 12 April 2007

Acceptance publication date 23 December 2010

International Classifications

C07D 513/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61K 31/429 (2006.01) - condensed with heterocyclic ring systems

A61K 31/433 (2006.01) - Thiadiazoles

A61K 31/4402 (2006.01) - only substituted in position 2, e.g. pheniramine, bisacodyl

A61K 31/505 (2006.01) - Pyrimidines

C07D 213/75 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 231/40 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

C07D 239/42 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 239/84 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 241/20 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

C07D 277/46 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

C07D 277/82 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

C07D 285/135 (2006.01) Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups

Event Publications

10 April 2008 PCT application entered the National Phase

  PCT publication WO2007/041366 Priority application(s): WO2007/041366

23 December 2010 Application Accepted

  Published as AU-B-2006297128

21 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006297129-Oral composition containing a salivation inducing agent

2006297127-3-cyclyl-2- (4-sulfamo yl-phenyl) - n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes